Spherix Incorporated (NASDAQ:SPEX) announced that its drug candidate, SPX-106, achieved statistically significant reductions in VLDL and LDL cholesterol when administered in combination with Dtagatose (SPX-106T) for nine weeks to genetically engineered mice prone to dyslipidemia. The aortas of these mice also showed reductions in the extent of atherosclerotic lesions as measured by lesion area in response to treatment. These lipoprotein analysis and lesion measurement results represent the final data from the study whose earlier triglycerides outcome was first announced on June 2, 2011.

Spherix Incorporated, together with its subsidiaries, engages in the development of pharmaceutical products. It is developing D-tagatose that completed Phase 3 clinical trials for the treatment of type 2 diabetes.

Read more at: http://pennytobuck.com/?p=16949